Last updated on February 2017

A 15-week, Phase 2, Double Blind, Randomized, Placebo-controlled, Flexible Dose Study To Investigate The Efficacy, Safety And Tolerability Of Pf-06649751 In Subjects With Early Stage Parkinson's Disease


Brief description of study

A 15-week, Phase 2, Double Blind, Randomized, Placebo-controlled, Flexible Dose Study To Investigate The Efficacy, Safety And Tolerability Of Pf-06649751 In Subjects With Early Stage Parkinson's Disease

Detailed Study Description

The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients at early stage of the disease.

Clinical Study Identifier: TX147428

Contact Investigators or Research Sites near you

Start Over

Kevin Allison or Mary Freeman

University of South Florida - Morsani Center for Advanced Healthcare
Tampa, FL USA
  Connect »

Leigh Donharl

University of South Florida - USF Health Byrd Alzheimer's Institute
Tampa, FL USA
  Connect »